An estimated 3 million people in the U.S. have atrial fibrillation and as many as 12 million people will have the condition by 2050. Today, 2050

The THERMOCOOL® SMARTTOUCH® Catheter is the first device of its kind approved in the U.S. to feature direct contact force technology for the treatment of drug resistant paroxysmal atrial fibrillation (AfiB).

Data from the trial that studied the safety and effectiveness of the THERMOCOOL® SMARTTOUCH® Catheter showed higher success rates the longer physicians stayed within a targeted contact force range.

AFIB FACTS

The THERMOCOOL® SMARTTOUCH® Catheter enhances a physician’s ability to achieve stable application of contact force by providing direct, real-time quantitative feedback graphically displayed on the CARTO® 3 System monitor upon tissue contact.

Catheter inserted through leg vein

CARTO® 3 SYSTEM

The THERMOCOOL® SMARTTOUCH® Catheter sends contact force readings to Biosense Webster, Inc.’s CARTO® 3 System, which provides real-time 3D maps of the heart during the minimally invasive catheter ablation procedures.

During catheter ablation, a thin flexible tube called a catheter is inserted through a blood vessel in the leg and guided to the heart. Radio frequency energy is delivered to target areas in the heart to address abnormal electrical signals.

AFIB FACTS

People with AfiB have five times greater risk for stroke.

Some people with AfiB liken the feeling of an episode to a hummingbird flapping its wings in their chest.

During AfiB, the atria may beat as often as 350 times a minute, about four times faster than normal.

©Biosense Webster, Inc. 2014

AFIB FACTS

An estimated 3 million people in the U.S. have atrial fibrillation and as many as 12 million people will have the condition by 2050.